HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

GPR30 decreases cardiac chymase/angiotensin II by inhibiting local mast cell number.

Abstract
Chronic activation of the novel estrogen receptor GPR30 by its agonist G1 mitigates the adverse effects of estrogen (E2) loss on cardiac structure and function. Using the ovariectomized (OVX) mRen2.Lewis rat, an E2-sensitive model of diastolic dysfunction, we found that E2 status is inversely correlated with local cardiac angiotensin II (Ang II) levels, likely via Ang I/chymase-mediated production. Since chymase is released from cardiac mast cells during stress (e.g., volume/pressure overload, inflammation), we hypothesized that GPR30-related cardioprotection after E2 loss might occur through its opposing actions on cardiac mast cell proliferation and chymase production. Using real-time quantitative PCR, immunohistochemistry, and immunoblot analysis, we found mast cell number, chymase expression, and cardiac Ang II levels were significantly increased in the hearts of OVX-compared to ovary-intact mRen2.Lewis rats and the GPR30 agonist G1 (50 mg/kg/day, s.c.) administered for 2 weeks limited the adverse effects of estrogen loss. In vitro studies revealed that GPR30 receptors are expressed in the RBL-2H3 mast cell line and G1 inhibits serum-induced cell proliferation in a dose-dependent manner, as determined by cell counting, BrdU incorporation assay, and Ki-67 staining. Using specific antagonists to estrogen receptors, blockage of GPR30, but not ERα or ERβ, attenuated the inhibitory effects of estrogen on BrdU incorporation in RBL-2H3 cells. Further study of the mechanism underlying the effect on cell proliferation showed that G1 inhibits cyclin-dependent kinase 1 (CDK1) mRNA and protein expression in RBL-2H3 cells in a dose-dependent manner.
AuthorsZhuo Zhao, Hao Wang, Marina Lin, Leanne Groban
JournalBiochemical and biophysical research communications (Biochem Biophys Res Commun) Vol. 459 Issue 1 Pg. 131-6 (Mar 27 2015) ISSN: 1090-2104 [Electronic] United States
PMID25712524 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone
  • Cyclopentanes
  • Estrogen Receptor Antagonists
  • Estrogens
  • Gper1 protein, rat
  • Quinolines
  • Receptors, G-Protein-Coupled
  • Angiotensin II
  • Estradiol
  • CDC2 Protein Kinase
  • Cdk1 protein, rat
  • Cyclin-Dependent Kinases
  • Chymases
Topics
  • Angiotensin II (metabolism)
  • Animals
  • CDC2 Protein Kinase
  • Cell Line
  • Cell Proliferation (drug effects)
  • Chymases (metabolism)
  • Cyclin-Dependent Kinases (metabolism)
  • Cyclopentanes (pharmacology)
  • Estradiol (metabolism, pharmacology)
  • Estrogen Receptor Antagonists (pharmacology)
  • Estrogens (metabolism)
  • Female
  • Mast Cells (cytology, drug effects, physiology)
  • Myocardium (cytology, metabolism)
  • Ovariectomy
  • Quinolines (pharmacology)
  • Rats, Inbred Lew
  • Receptors, G-Protein-Coupled (agonists, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: